Treatment for Prostate Cancer

Phase-Based Progress Estimates
Prostate Cancer+11 More
All Sexes
What conditions do you have?

Study Summary

This trial is testing a weight loss program for overweight and obese cancer survivors in Maryland.

Eligible Conditions
  • Prostate Cancer
  • Renal Cancers
  • Breast Cancer
  • Malignant Melanoma of Skin
  • Bladder Cancer, Cancer
  • Rectal Carcinoma
  • Cancer of the Gallbladder
  • Endometrial Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Prostate Cancer

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: End of enrollment, up to 2 years

6 months
Adoption of weight loss program activities as assessed by app use frequency
Implementation of weight loss program as assessed by a participant survey
Baseline and 12 months
Weight change at 12 months by program
Baseline and 6 months
Weight change at 6 months in Coach-Directed Program
Weight change at 6 months in Self-Directed and App-Directed Weight Loss Programs
Year 2
Program participation as assessed by participant enrollment

Trial Safety

Safety Progress

1 of 3

Other trials for Prostate Cancer

Trial Design

0 Treatment Group

300 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: end of enrollment, up to 2 years

Who is running the clinical trial?

Maryland Cigarette Restitution FundOTHER_GOV
4 Previous Clinical Trials
352 Total Patients Enrolled
1 Trials studying Prostate Cancer
121 Patients Enrolled for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
534 Previous Clinical Trials
30,812 Total Patients Enrolled
51 Trials studying Prostate Cancer
2,685 Patients Enrolled for Prostate Cancer
Jessica Yeh, Ph.D.Principal InvestigatorJohns Hopkins University

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
She had been diagnosed with a tumor before.
They anticipate the treatment-free life span to be at least 12 months long.
This means that chemoprophylaxis with tamoxifen or aromatase inhibitors for breast cancer in women will be allowed.
The text states that the person must have completed all required surgery, chemotherapy and radiation therapy at least three months prior to enrolling in the study.
The prostate cancer therapy that uses anti-Luteinizing-hormone releasing hormone will be allowed.
Email addresses can be used for regular, personal use.
study The study will only include participants who are able to track their weight on their own and/or through an app.
For someone to be classified as obese according to the BMI, their BMI must be ≥ 25 kg/m2 and their weight must be ≤ 400 lbs.
The person is willing to record or transmit their weight every three months for a year.
The person is willing to make changes to their diet and increase their physical activity in order to track their weight, diet and physical activity.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: October 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.